BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

590 related articles for article (PubMed ID: 8594268)

  • 1. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination.
    King GE; Markowitz LE; Heath J; Redd SC; Coleman S; Bellini WJ; Sievert A
    JAMA; 1996 Mar; 275(9):704-7. PubMed ID: 8594268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody response to measles-mumps-rubella vaccine of children with mild illness at the time of vaccination. Should we be concerned?
    Watada B; Kennedy K; Chan D; Church B; Patriquin M; Shariff F; Evans MF
    Can Fam Physician; 1998 Jan; 44():53-5. PubMed ID: 9481462
    [No Abstract]   [Full Text] [Related]  

  • 3. Seroconversion rates to combined measles-mumps-rubella-varicella vaccine of children with upper respiratory tract infection.
    Dennehy PH; Saracen CL; Peter G
    Pediatrics; 1994 Oct; 94(4 Pt 1):514-6. PubMed ID: 7936862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serologic response to measles-mumps-rubella vaccine among children with upper respiratory tract infection.
    Cilla G; Peña B; Marimón JM; Pérez-Trallero E
    Vaccine; 1996 Apr; 14(6):492-4. PubMed ID: 8782345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The combination measles, mumps, rubella and varicella vaccine in healthy children.
    Arbeter AM; Baker L; Starr SE; Plotkin SA
    Dev Biol Stand; 1986; 65():89-93. PubMed ID: 3030864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to measles, mumps and rubella vaccine in paediatric bone marrow transplant recipients.
    King SM; Saunders EF; Petric M; Gold R
    Bone Marrow Transplant; 1996 Apr; 17(4):633-6. PubMed ID: 8722367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measles and rubella antibody response after measles-mumps-rubella vaccination in children with afebrile upper respiratory tract infection.
    Ratnam S; West R; Gadag V
    J Pediatr; 1995 Sep; 127(3):432-4. PubMed ID: 7658276
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and immunogenicity of a combined live attenuated measles, mumps, rubella, and varicella vaccine (MMR(II)V) in healthy children.
    Watson BM; Laufer DS; Kuter BJ; Staehle B; White CJ; Starr SE
    J Infect Dis; 1996 Mar; 173(3):731-4. PubMed ID: 8627041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of a combined measles-mumps-rubella-chickenpox vaccine.
    Just M; Berger R; Just V
    Dev Biol Stand; 1986; 65():85-8. PubMed ID: 3030863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunity to and immunization against measles, rubella and mumps in patients after autologous bone marrow transplantation.
    Pauksen K; Duraj V; Ljungman P; Sjölin J; Oberg G; Lönnerholm G; Fridell E; Smedmyr B; Simonsson B
    Bone Marrow Transplant; 1992 Jun; 9(6):427-32. PubMed ID: 1628126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Decreased measles antibody response after measles-mumps-rubella vaccine in infants with colds.
    Krober MS; Stracener CE; Bass JW
    JAMA; 1991 Apr; 265(16):2095-6. PubMed ID: 2013930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative evaluation of two combined measles-mumps-rubella vaccines based on AIK and Edmonston- Zagreb strains of measles virus.
    Mirchamsy H; Nilforoushan MA; Shafyi A; Razavi J; Ashtiani MP; Youssofi I; Sassani A; Fateh G; Nassiri S
    Kitasato Arch Exp Med; 1991 Sep; 64(2-3):141-7. PubMed ID: 1811112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decline in rates of seropositivity for measles, mumps, and rubella antibodies among previously immunized children treated for acute leukemia.
    Feldman S; Andrew M; Norris M; McIntyre B; Iyer R
    Clin Infect Dis; 1998 Aug; 27(2):388-90. PubMed ID: 9709893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of antibodies to measles, mumps, and rubella among Thai population: evaluation of measles/MMR immunization programme.
    Tharmaphornpilas P; Yoocharean P; Rasdjarmrearnsook AO; Theamboonlers A; Poovorawan Y
    J Health Popul Nutr; 2009 Feb; 27(1):80-6. PubMed ID: 19248651
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Changes of the immunological patterns against measles, mumps and rubella. A vaccination programme studied 3 to 7 years after the introduction of a two-dose schedule.
    Christenson B; Böttiger M
    Vaccine; 1991 May; 9(5):326-9. PubMed ID: 1872016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measles, mumps and rubella immunisation in children at risk of infection with human immunodeficiency virus.
    Molyneaux PJ; Mok JY; Burns SM; Yap PL
    J Infect; 1993 Nov; 27(3):251-3. PubMed ID: 8308316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of live attenuated varicella vaccine (Oka-RIT strain) and combined varicella and MMR vaccination in 13-17-month-old children.
    Vesikari T; Ohrling A; Baer M; Delem A; Bogaerts H; André FE
    Acta Paediatr Scand; 1991 Nov; 80(11):1051-7. PubMed ID: 1661057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The immunological efficacy of the combined vaccine Trimovax intended for the prevention of measles, mumps and rubella].
    Samoĭlovich EO; Kapustik LA; Fel'dman EV; Ermolovich MA; Svirchevskaia EIu; Titov LP; Zakharenko DF; Belova EIu; Chernovetskiĭ MA; Korostik TS
    Zh Mikrobiol Epidemiol Immunobiol; 1998; (4):36-40. PubMed ID: 9783398
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.